Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2019 | Story Rulanzen Martin | Photo Supplied
Prof Albert Weideman
Prof Albert Weideman has designed language tests for South African institutions as well as universities in Namibia, Vietnam, Singapore, the Netherlands, and Australia

Prof Albert Weideman became involved in language testing in the 1980s and almost 40 years later, the South African Association for Language Teaching (SAALT) has now honoured him with a Lifetime Achievement Award for “his contribution to research and practice in applied linguistics, test design, and curriculum development in academic literacy”.

“It’s a wonderful honour to be recognised in one’s field in this way and I am humbled by the many congratulatory messages I have received from as far afield as the Netherlands, the US and Australia,” says Prof Weideman, senior research fellow in the Department of South African Sign Language and Deaf Studies at the University of the Free State (UFS). 

“I wish to dedicate it to the many dozens of MA students I have had, as well as to the many talented PhD students I have supervised,” he said upon receiving the award at the SAALT conference which was held at the University of Pretoria recently. 

Pioneer in the field of language assessment 

“His creative designs have enhanced the quality of academic literacy tests in South Africa,” says Prof Theodorus du Plessis, head of the Department of South African Language and Deaf Studies. The language courses which Prof Weideman has developed have been used at beginner, intermediate and advanced level, as well as for introducing teachers to innovations in language teaching.

During his career Prof Weideman has witnessed an interesting change in the assessment of language: “The focus of language testing has shifted from testing the so-called ‘skills’ of reading, writing, listening and speaking, to measuring communicative ability,” he says. 

He is very excited about the impact of the Fourth Industrial Revolution on language teaching, specifically when it comes to “computer adaptive language testing, and language-course delivery in a multiplicity of new media.”


News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept